Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide Susmita Roy25 Oct 2025 4:13 PM ISTNew Delhi: Pharmaceutical major Sun Pharma Laboratories has got the go ahead from the Subject Expert Committee (SEC) functional under the Central...
Study confirms cardiovascular benefits of semaglutide beyond weight loss: LANCET Dr. Kamal Kant Kohli25 Oct 2025 8:30 AM ISTA new analysis of the SELECT trial-the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication...
CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens Susmita Roy23 Oct 2025 1:28 PM ISTNew Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organization (CDSCO), has opined that Macleods...
FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 Diabetes Dr. Kamal Kant Kohli23 Oct 2025 9:00 AM ISTThe FDA has approved oral semaglutide (Rybelsus) 7 mg and 14 mg tablets to lower the risk of cardiovascular death, heart attack, or stroke in...
Biocon Told to Submit Detailed Toxicity, SAE Data on Semaglutide Prefilled Pen After Animal Deaths Susmita Roy21 Oct 2025 1:00 PM ISTNew Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has opined that Biocon...
Comparable Cardiorenal Outcomes Among Three GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes: JAMA Medha Baranwal18 Oct 2025 9:00 AM ISTUSA: A retrospective comparative effectiveness study among veterans with type 2 diabetes found that three GLP-1 receptor agonists-semaglutide,...
Alkem Labs Gets CDSCO Panel Nod for conducting Phase III study of Semaglutide tablet Susmita Roy14 Oct 2025 5:23 PM ISTNew Delhi: Alkem Laboratories has got the go-ahead from the Subject Expert Committee (SEC), functioning under the Central Drug Standard Control...
CDSCO Panel seeks clarifications from Novo Nordisk on IcoSema phase IIIb clinical study protocol Susmita Roy11 Oct 2025 9:46 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has opined that Novo Nordisk India should...
New EASO guidance recommends semaglutide and tirzepatide as first-line treatments for obesity and its major complications Dr. Kamal Kant Kohli6 Oct 2025 8:30 AM ISTSemaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new...
Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial Deeksha Bhandari3 Oct 2025 12:09 PM ISTSURMOUNT-5 was a 72-week, Phase 3b, multicenter, randomized, open-label, comparator-controlled study that evaluated the efficacy and safety of...
Once-Weekly Semaglutide bests Sitagliptin for blood sugar, Weight, and Lipid Profile control in T2DM: Study Medha Baranwal26 Sept 2025 9:30 AM ISTHungary: Researchers have found in a new study that once-weekly semaglutide significantly reduces weight and HbA1c while favorably modifying...
Taking semaglutide turns down food noise, research suggests Dr. Kamal Kant Kohli23 Sept 2025 8:30 PM ISTFood noise refers to obsessive and intrusive thoughts about food and eating. This preoccupation with food can hinder healthy lifestyle implementation...
